<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="at: [[inbox]]
Oncology - Neutropenic Fever - Fast Facts | NEJM Resident 360 Fever during chemotherapy-induced neutropenia may be the earliest sign of infection and should be taken seriouslyÂ since immunosuppressed patients may not exhibit the typical inflammatory signs of infection."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Oncology - Neutropenic Fever - Fast Facts | NEJM Resident 360"><title>Oncology - Neutropenic Fever - Fast Facts | NEJM Resident 360</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.02120ee5abce9b994b1487466af3b5e4.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.5b83f749048f13c9288e6ddafdf78a71.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=æœå°‹ placeholder="è«‹è¼¸å…¥åƒæ˜¯ï¼šhypertension ä¹‹é¡çš„ä¾†çœ‹æ²’æœ‰æ²’ä»€éº¼æœ‰è¶£çš„ğŸ³"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</a></h1><div class=spacer></div><div id=search-icon><p>æœå°‹</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">æœå°‹åœ–ç¤º</title><desc id="desc">æ‰“é–‹æœå°‹åœ–æ¨™</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>æ˜äº®æ¨¡å¼</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>é»‘æš—æ¨¡å¼</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Oncology - Neutropenic Fever - Fast Facts | NEJM Resident 360</h1><p class=meta>æœ€å¾Œæ›´æ–°æ–¼
Feb 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Oncology%20-%20Neutropenic%20Fever%20-%20Fast%20Facts%20%20NEJM%20Resident%20360.md rel=noopener>ğŸªš ç·¨è¼¯åŸå§‹æ–‡ä»¶</a></p><ul class=tags></ul><p>at: <a class="internal-link broken">inbox</a></p><a href=#oncology---neutropenic-fever---fast-facts--nejm-resident-360><h1 id=oncology---neutropenic-fever---fast-facts--nejm-resident-360><span class=hanchor arialabel=Anchor># </span>Oncology - Neutropenic Fever - Fast Facts | NEJM Resident 360</h1></a><p>Fever during chemotherapy-induced neutropenia may be the earliest sign of infection and should be taken seriouslyÂ since immunosuppressed patients may not exhibit the typical inflammatory signs of infection.</p><p>Neutropenic fever is defined as:</p><ul><li><p>single oral temperature of â‰¥38.3Â°C (101Â°F) or a temperature of â‰¥38.0Â°C (100.4Â°F) sustained for â‰¥1 hour</p></li><li><p><em>and</em> absolute neutrophil count (ANC) &lt;500 cells/mm<sup>3</sup> (or anticipated to decrease to &lt;500 cells/mm<sup>3</sup> in the next 48 hours)</p></li></ul><a href=#risk-stratification><h3 id=risk-stratification><span class=hanchor arialabel=Anchor># </span>Risk Stratification</h3></a><p>An infectious etiology underlying neutropenic fever is identified in only 40â€“50% of patients. However, most patients presenting with neutropenic fever should be hospitalized to receive empiric antibiotic therapy. Rarely, low-risk patients with anticipated brief duration (&lt;7 days) of neutropenia and minimal comorbid conditions can be treated as outpatients with oral antibiotic therapy and close follow-up. TheÂ Multinational Association for Supportive Care in Cancer (MASCC) Risk-Index scoreÂ may be used to stratify the risk of complications in patients with neutropenic fever (a score &lt;21 is considered high risk; see risk index score below andÂ here).</p><a href=#the-multinational-association-for-supportive-care-in-cancer-mascc-score><h3 id=the-multinational-association-for-supportive-care-in-cancer-mascc-score><span class=hanchor arialabel=Anchor># </span>The Multinational Association for Supportive Care in Cancer (MASCC) Score</h3></a><table><thead><tr><th>Characteristic</th><th>Weight</th></tr></thead><tbody><tr><td>Burden of febrile neutropenia</td><td></td></tr><tr><td>No or mild symptoms</td><td>5</td></tr><tr><td>Moderate symptoms</td><td>3</td></tr><tr><td>No hypotension (SBP > 90 mm Hg)</td><td>5</td></tr><tr><td>No active COPD</td><td>4</td></tr><tr><td>Solid tumor or no previous fungal infection</td><td>4</td></tr><tr><td>No dehydration requiring parenteral fluids</td><td>3</td></tr><tr><td>Outpatient status</td><td>3</td></tr><tr><td>Age &lt; 60 years</td><td>2</td></tr></tbody></table><a href=#note-applicable-points-are-added-to-create-a-cumulative-score-the-maximum-score-is-26-and-a-score-of-greater-than-20-has-a-predicted-low-risk--10-for-serious-medical-complications-during-the-course-of-the-febrile-neutropenia><h6 id=note-applicable-points-are-added-to-create-a-cumulative-score-the-maximum-score-is-26-and-a-score-of-greater-than-20-has-a-predicted-low-risk--10-for-serious-medical-complications-during-the-course-of-the-febrile-neutropenia><span class=hanchor arialabel=Anchor># </span>Note: Applicable points are added to create a cumulative score. The maximum score is 26, and a score of greater than 20 has a predicted low risk (&lt; 10%) for serious medical complications during the course of the febrile neutropenia.</h6></a><p>Abbreviations: COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure.<br>(Reference: Optimal Management of Neutropenic Fever in Patients with Cancer. J Oncol Pract 2019.)</p><a href=#diagnostic-workup><h3 id=diagnostic-workup><span class=hanchor arialabel=Anchor># </span>Diagnostic Workup</h3></a><p>Patients presenting with febrile neutropenia should undergo a detailed history and physical examination.</p><a href=#flowchart-of-a-patient-with-neutropenic-fever><h3 id=flowchart-of-a-patient-with-neutropenic-fever><span class=hanchor arialabel=Anchor># </span>Flowchart of a Patient with Neutropenic Fever</h3></a><p><strong>â€ Indications to add vancomycin include hemodynamic instability, skin or catheter site infection, concern for methicillin-resistant Staphylococcus aureus pneumonia, and blood cultures with gram-positive bacteria before final identification and susceptibilities.<br>Abbreviations: ANC, absolute neutrophil count; ESBL, extended-spectrum b-lactamase; HCT, hematopoietic cell transplantation; IV, intravenous; MASCC, Multinational Association for Supportive Care in Cancer.<br>(Source: Optimal Management of Neutropenic Fever in Patients with Cancer. J Oncol Pract 2019.)</strong></p><p>Initial evaluation includes the following:</p><ul><li><p><strong>complete history and physical</strong>Â are crucial to identify a focus of infection</p></li><li><p><strong>laboratory tests:</strong> complete blood count with differential, electrolytes, creatinine, blood urea nitrogen, liver function tests, and lactate</p></li><li><p><strong>routine blood cultures:</strong> at least two sets, if the patient has a central venous catheter, one set from the catheter and one peripheral</p></li><li><p><strong>urinalysis and urine culture</strong></p></li><li><p><strong>chest radiograph:</strong> in patients with respiratory signs or symptoms</p></li><li><p><strong>symptom-directed workup:</strong>Â cultures from any other sites of suspected infection (e.g., cerebrospinal fluid, wounds, lower respiratory tract)Â and/or imaging (e.g., abdominal and pelvic CT in patients with GI symptoms)</p></li><li><p><strong>viral nasopharyngeal swabs:</strong> in patients presenting with flu-like illness</p></li></ul><a href=#management><h3 id=management><span class=hanchor arialabel=Anchor># </span>Management</h3></a><p><strong>Antibiotic treatment:</strong></p><ul><li><p>Low-risk patients with febrile neutropenia should receive initial doses of empirical antibacterial therapy within 1 hour of triage and monitored for â‰¥4 hours before discharge. An oral fluoroquinolone plus amoxicillin/clavulanate (or clindamycin, if allergy to penicillin) is recommended as empirical outpatient therapy, unless fluoroquinolone prophylaxis was used before fever developed. Patients who do not defervesce after 2 to 3 days of an initial, empirical, broad-spectrum antibiotic regimen should be reevaluated and considered as candidates for inpatient treatment.</p></li><li><p>High-risk patients should be started on empiric antipseudomonal monotherapy with either cefepime or ceftazidime, or if allergic, a carbapenem or piperacillinâ€“tazobactam (algorithm varies by institutional standards and local resistance patterns).</p></li><li><p>Other antibiotics may be added for specific complications or known/suspected antimicrobial resistance.</p></li><li><p>Vancomycin is generally not administered empirically except in special circumstances (including suspected catheter-related infection, pneumonia, hemodynamic instability, or skin or soft tissue infection). If vancomycin is given, it should be discontinued after 48 hours if cultures remain negative and there is no evidence of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA).</p></li><li><p>Patients with a history of antibiotic-resistant organisms may require alternative regimens.</p></li><li><p>Antibiotic regimens may be modified as clinical and laboratory data results become available. (However, antipseudomonal coverage should typically continue until absolute neutrophil count [ANC] recovers to >500 cells/mm<sup>3</sup>.)</p></li><li><p>Patients who remain unstable after initial standard neutropenic-fever management should have their regimen broadened to include coverage for resistant gram-negative, gram-positive, and anaerobic bacteria and fungi.</p></li><li><p>After 4â€“7 days of broad-spectrum antibiotics, empiric antifungal coverage should be added in high-risk patients with persistent fever with no documented source. Treatment regimens include micafungin or liposomal amphotericin B and should be decided in conjunction with an infectious disease (ID) consultation.</p></li></ul><a href=#flowchart-of-risk-assessment-72-hours-after-initiating-empirical-antibiotic-therapy><h3 id=flowchart-of-risk-assessment-72-hours-after-initiating-empirical-antibiotic-therapy><span class=hanchor arialabel=Anchor># </span>Flowchart of Risk Assessment 72 Hours after Initiating Empirical Antibiotic Therapy</h3></a><p><strong>(Source: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America.Â Clin Infect Dis 2011.)</strong></p><p><strong>Indications for granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF):</strong></p><ul><li><p>often administered prophylactically after chemotherapy regimens associated with high incidence of neutropenic fever (seeÂ Table 1. Risk of Febrile Neutropenia, According to the Type of Cancer and Chemotherapy Regimen)</p></li><li><p>may be given prophylactically after low- or intermediate-risk chemotherapy regimens in older patients or patients with high-risk comorbidities</p></li><li><p>may be given to patients who do not receive prophylaxis but do not recover granulocyte counts to facilitate adherence to planned chemotherapy schedule in curative situations</p></li><li><p>may be given to patients with neutropenic fever with high risk for infection-associated complications or factors predictive of poor outcome</p></li></ul><p><strong>Prophylaxis for neutropenic fever</strong>**:** Antibiotic prophylaxis is recommended for patients who are at high risk for bacteremia and/or fungaemia, including patients who are expected to have profound, protracted neutropenia (defined as &lt;100 neutrophils/ÂµL for >7 days) or other risk factors. Although institutional practices may vary, some general guidelines for antimicrobial prophylaxis are as follows:</p><ul><li><p>Antibacterial prophylaxis with levofloxacin or ciprofloxacin to prevent <em>Pneumocystis jirovecii</em> infection is recommended in high-risk patients, including those undergoing allogenic hematopoietic cell transplantation (HCT) and those receiving induction chemotherapy for acute leukemia.</p></li><li><p>Antifungal prophylaxis with oral triazole or parenteral echnocandin is recommended for patients with acute myeloid leukemia, myelodysplastic syndrome, and/or patients treated with HCT.</p></li><li><p>Antiviral prophylaxis with acyclovir or valacyclovir is recommended for patients seropositive for herpes simplex virus who are undergoing allogeneic HCT, patients undergoing induction chemotherapy for acute leukemia, and patients seropositive for varicella zoster virus.</p></li></ul><p><a class="internal-link broken">inbox</a></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>â†©ï¸ åå‘é€£çµ</h3><ul class=backlinks><li><a href=/all-list-of-resident360/ data-ctx="Oncology - Neutropenic Fever - Fast Facts  NEJM Resident 360" data-src=/all-list-of-resident360 class=internal-link>all list of resident360</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ğŸ¤¯äº’å‹•åœ–</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>æœ¬ç¶²ç«™æ˜¯ç”± Hsieh-Ting Lin ä»¥â¤ï¸ ç”¨ <a href=https://github.com/jackyzha0/quartz>Quartz</a>é€™å€‹é…·æ±è¥¿ç¨®å‡ºä¾†ğŸª´ , Â© 2023</p><ul><li><a href=https://www.physician.tw/>ğŸ é¦–é </a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>